Government Operations committee  I don't think it's an infinite number, but certainly it's more than two or three that provinces can indicate. My colleague Ms. Reza can perhaps offer some additional context on the volume of POUs in play.

Government Operations committee  It can be. I can't speak to actual locations. Arianne might have more context there.

Government Operations committee  Just to answer the question, the decision does rest with the provinces and territories.

Government Operations committee  There are limits in terms of how many, but it's more than two or three, as Arianne mentioned.

Government Operations committee  Medicago is still going through trials. They're an interesting candidate in terms of the technology, being protein-based. We don't have any firm dates on when they'll pass through the various hurdles, but they're still going through trials. It's certainly something that we're kee

Government Operations committee  There is diversification across a number of fronts, and I would say that number one is the various platforms. Pfizer and Moderna have a similar platform. Then there's Johnson & Johnson and AstraZeneca, with the viral vector, and for the more traditional protein subunit, there

Government Operations committee  The contract is for a number of doses, so number of vials doesn't actually count. The number of doses is based on the label that goes with the product, so effectively—

Government Operations committee  We effectively started counting differently when the regulatory change was made, in terms of their deliveries against the contract.

Government Operations committee  We were paying for the number of doses extracted, under the regulatory approval. In fact, early on, in many cases provinces were actually squeezing extra doses out of the vial.

Government Operations committee  There's no retroactive piece here, Mr. Chair. It is number of doses delivered. The second the regulatory change was made, we started counting doses differently going forward.

Government Operations committee  It's a hypothetical on all of that, and I can't speak, given the sensitivity of the contracts, Mr. Chair, at this time.

Government Operations committee  Normally speaking, when you're dealing with vaccines or therapeutics, the hooks in the contract relate to regulatory approval. That's a key hurdle, from a contractual perspective.

Government Operations committee  I can't get into the specifics of the contracts, but I have shared that the regulatory approval is, obviously, a key hurdle in terms of respecting the contract. There's not much more I can offer at this stage.

Government Operations committee  Typically, Mr. Chair—and I can't speak specifically to this one—the actual content or the advertising choices are the responsibility of the department—

Government Operations committee  In terms of the sponsoring department, if I recall correctly, it would have been Health on this one, because the actual content is COVID awareness, but we can check back on that, Mr. Chair.